Literature DB >> 31974627

CYP2E1 changes the biological function of gastric cancer cells via the PI3K/Akt/mTOR signaling pathway.

Rui-Ying Wang1, Xiao-Wei Chen1, Wen-Wen Zhang1, Fei Jiang1, Meng-Qi Liu1, Xiao-Bing Shen1.   

Abstract

The present study investigated the role of cytochrome P450 family 2 subfamily E polypeptide 1 (CYP2E1) in the development and progression of gastric cancer (GC). The expression levels of CYP2E1 in MGC‑803 GC cells and normal GES‑1 cells were investigated via western blotting, and it was identified that the expression of CYP2E1 was different between GES‑1 and MGC‑803 cells. CYP2E1 was overexpressed in MGC‑803 cells using a lentiviral vector GV358. Cell Counting Kit‑8, flow cytometry, cell migration and Matrigel invasion assays suggested that overexpression of CYP2E1 promoted the proliferation and invasion, and inhibited the apoptosis of GC cells. The relationship between CYP2E1 expression and key signaling molecules in the PI3K/Akt/mTOR signaling pathway was assessed. Reverse transcription‑quantitative PCR analysis showed that mTOR mRNA expression was significantly increased after overexpression of CYP2E1 (P<0.05). Western blotting results showed that overexpression of CYP2E1 upregulated the expression of phosphorylated (p)‑Akt, p‑mTOR and p‑p70 ribosomal protein S6 kinase (P70S6K; Ser371) proteins (P<0.05). To further investigate the relationship between CYP2E1 and the PI3K/Akt/mTOR signaling pathway in GC cells, MGC‑803 cells were treated with the PI3K inhibitor LY294002, and changes in the expression levels of PI3K, AKT, mTOR, P70S6K and CYP2E1 were observed. The present results showed that LY294002 downregulated the expression of PI3K, CYP2E1, AKT, mTOR and P70S6K (P<0.05). Therefore, changes in the biological function of GC cells induced by CYP2E1 overexpression may be via the PI3K/Akt/mTOR signaling pathway.

Entities:  

Year:  2019        PMID: 31974627     DOI: 10.3892/mmr.2019.10890

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

1.  CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma.

Authors:  Chen Zhang; Jinqiu Zhao; Jie Zhao; Bohao Liu; Wenbin Tang; Yi Liu; Wenxiang Huang; Steven A Weinman; Zhuan Li
Journal:  Cancer Gene Ther       Date:  2022-07-28       Impact factor: 5.854

2.  High-Risk HPV with Multiple Infections Promotes CYP2E1, Lipoperoxidation and Pro-Inflammatory Cytokines in Semen of Asymptomatic Infertile Men.

Authors:  Elvia Pérez-Soto; María Olivia Medel-Flores; Eduardo Fernández-Martínez; Rigoberto Oros-Pantoja; José Cruz Miranda-Covarrubias; Virginia Sánchez-Monroy
Journal:  Antioxidants (Basel)       Date:  2022-05-26

3.  Potential pathogenetic link between angiomyofibroblastoma and superficial myofibroblastoma in the female lower genital tract based on a novel MTG1-CYP2E1 fusion.

Authors:  Ryosuke Tajiri; Eisuke Shiba; Ryuji Iwamura; Chisachi Kubo; Aya Nawata; Hiroshi Harada; Kiyoshi Yoshino; Masanori Hisaoka
Journal:  Mod Pathol       Date:  2021-08-12       Impact factor: 7.842

Review 4.  Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.

Authors:  Nataliya Pidkovka; Olena Rachkevych; Abbes Belkhiri
Journal:  Oncotarget       Date:  2021-02-16

5.  Curcumin Inhibits the Proliferation of Renal Cancer 786-O Cells through MTOR Signaling Pathway and Its Mechanism.

Authors:  Rui Gao; Yunfang Ma; Yali Wang; Haili Xu
Journal:  J Healthc Eng       Date:  2022-03-30       Impact factor: 2.682

6.  GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.

Authors:  Yuan Li; Yibo Fan; Jinbang Xu; Longfei Huo; Ailing W Scott; Jiankang Jin; Boxuan Yang; Shan Shao; Lang Ma; Ying Wang; Xiaodan Yao; Melissa Pool Pizzi; Matheus Sewastjanow Da Silva; Guoliang Zhang; Lijuan Zhuo; Eun Jeong Cho; Kevin N Dalby; Namita D Shanbhag; Zhenning Wang; Wenliang Li; Shumei Song; Jaffer A Ajani
Journal:  J Exp Clin Cancer Res       Date:  2022-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.